Phosphatidylserine-Omega-3 Impact on ADHD Symptoms in Adults with ADHD: A Randomized, Sequential Parallel, Double-Blind, Placebo-Controlled Trial

Background:

PS-Omega-3 is a unique composition that addresses lipid imbalances associated with ADHD. This composition has been clinically shown to significantly reduce ADHD symptoms, especially in children with emotional dysregulation. Additionally, this composition has been shown to be safe and well-tolerated in children. The aim of the present study was to evaluate the effect of an increased dose of PS-Omega-3 in managing ADHD in adults.

Methods:

189 ADHD adults were enrolled in a multi-center, randomized, double-blind, sequential parallel comparison design (SPCD) trail divided into two phases of 8 weeks. Participants were randomly assigned in a 1:1:1 ratio to receive PS-Omega-3 (4 capsules/day) for 16 weeks, placebo for 8 weeks followed by PS-Omega-3 (4 capsules/day) for 8 weeks or placebo for 16 weeks. The primary efficacy measure of the study was the Adult ADHD Investigator Symptom Rating Scale (AISRS). Other assessments tools included the Adult ADHD Self-Report Scale (ASRS) and Behavior Rating Inventory of Executive Function- Adult Version (BRIEF-A).

Results:

Significant greater reduction in the AISRS total score and the AISRS inattentive sub-scale were observed in the PS-Omega-3 group, compared to placebo. In addition, PS-Omega-3 group exhibited higher level of executive functions compared to the placebo group, as demonstrated by the BRIEF-A scores.

Conclusion:

These results demonstrate that PS-Omega 3 may improve ADHD symptoms and clinical features associated with ADHD in adults. These results further corroborate the findings observed in previous studies and suggest that PS-Omega-3 may play an important role in the management of ADHD.